Operator
Ladies and gentlemen, thank you for standing by. Welcome to the merger between Rallybio Corporation and Avenzo Therapeutics.
[Operator Instructions] Please be advised that today’s conference is being recorded.
I would like now to turn the conference over to Stephen Uden, Co-Founder and Chief Executive Officer. Please go ahead.
Steve Uden
Co-Founder, President, CEO & Director
Thanks, Michelle. Thank you, and good morning. Before we begin, I’d like to remind you that this discussion will contain forward-looking statements based upon the current expectations of Rallybio and Avenzo, which include, but are not limited to, statements regarding the expected timing, completion, effects and intended outcomes for the proposed transactions and our future expectations, plans and prospects for the combined company, including clinical development matters, use of proceeds, expected cash runway and expected milestones.
Such statements represent management’s judgment and intention as of today and involve assumptions, risks and uncertainties. Except to the extent required by law, we do not undertake any obligation to update any forward-looking statements. We also caution you against placing undue reliance on any forward-looking statements.
Further, as indicated on these slides, Rallybio intends to file a registration statement and accompanying proxy statement and prospectus with the Securities and Exchange Commission relating to the proposed transaction. Please be advised to read, when available, these and other relevant documents filed with the SEC. Please refer to the accompanying slides for more details on these forward-looking statements.
I will now turn the conference over to Dr. Athena Countouriotis, Chair, President and Chief Executive Officer of Avenzo Therapeutics. Athena?
